FDA advisers review SYD-101, low-dose atropine 0.01% for pediatric myopia, on Oct 30 after a 2025 complete response letter.
|Videos|July 22, 2021
Vyluma pipeline focuses on refractive error
Advertisement
Vyluma, which recently spun off from Nevakar, has a robust pipeline for potential therapies addressing refractive error. Navneet Puri, PhD, the company’s founder, chairman, and CEO, offers additional insights.
Advertisement
Related to this article
Christina M. Danley, OD, FOVDR, explores the many nuances that require consideration when answering a common question asked by parents of children with myopia.
Kevin Chan, OD, MS, discusses an AAOpt 2026 symposium on individualized low-dose atropine dosing for myopia and the FDA outlook ahead of the SYD-101 advisory meeting.
Kevin Chan, OD, MS, FAAO, FBCLA, IACMM, stated in his Rapid Fire lecture that high myopes shouldn't be counted out of orthokeratology treatment.
Magdalena Stec, OD, FAAO, and Noreen Shaikh, OD, MEd, FAAO, gave an overview of current evidence-based myopia control treatments in part of their AAOpt 2026 session.
This week's top stories include breaking FDA approvals, insights on AI-assisted front desk management, and more.
Open-access OCTA tools showed similar reliability, but different vessel density values in glaucoma; researchers advise using one tool consistently.
Interim 48-month data show 86% of patients with glaucoma or ocular hypertension remain off topical drops after a single cataract procedure, although the drop-free rate has eased from earlier timepoints.
Advertisement
Advertisement
Trending on Optometry Times - Clinical News & Expert Optometrist Insights
1
BIM-IOL System holds 37% IOP reduction at 4 years in first-in-human trial
2
Takeaways from this week in optometry: October 16-23
3
Brepocitinib for noninfectious uveitis meets all phase 3 trial end points
4
More than monitoring: Using AMD visits to promote healthy vision aging
5